BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38554335)

  • 21. Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study.
    Zheng SH; Huang JL; Chen M; Wang BL; Ou QS; Huang SY
    J Neurosurg; 2018 Sep; 129(3):583-592. PubMed ID: 29099300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
    Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
    Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments.
    Zhao X; Zhang N; Zhang H; Liu P; Ma J; Hu C; Liu X; Hou T
    Medicine (Baltimore); 2020 Nov; 99(46):e23150. PubMed ID: 33181687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
    Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
    Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
    Landre T; Des Guetz G; Chouahnia K; Duchemann B; Assié JB; Chouaid C
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3333-3339. PubMed ID: 32632581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of the neutrophil-to-lymphocyte ratio and primary tumor location in epidermal growth factor receptor-mutated metastatic non-small cell lung cancer.
    Xie X; Li X; Tang W; Chen J; Xie P; Li M
    J Cancer Res Ther; 2021 Dec; 17(7):1618-1625. PubMed ID: 35381730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
    Sari M; Aydiner A
    J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study.
    Mirili C; Paydaş S; Guney IB; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M; Seydaoglu G
    Cancer Manag Res; 2019; 11():3445-3453. PubMed ID: 31114378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
    BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
    Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
    Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
    Akazawa Y; Igawa S; Yamada K; Yamamoto H; Yagami Y; Kaizuka N; Manaka H; Kasajima M; Nakahara Y; Sato T; Mitsufuji H; Yokoba M; Kubota M; Sasaki J; Naoki K
    Oncology; 2023; 101(11):685-694. PubMed ID: 37166346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced
    Ortega-Granados AL; Artal-Cortes Á; Aguiar-Bujanda D; Oramas J; Fírvida JL; DE Castro J; Fuentes JC; Gordo R; Galán R; Trigo J;
    Anticancer Res; 2019 Mar; 39(3):1317-1328. PubMed ID: 30842164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
    Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
    Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COMPLETE BLOOD COUNT DERIVED INFLAMMATORY BIOMARKERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
    Nanava N; Betaneli M; Giorgobiani G; Chikovani T; Janikashvili N
    Georgian Med News; 2020 May; (302):39-44. PubMed ID: 32672687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
    Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M
    BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
    Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer.
    Liu K; Jiang G; Fang N; Cai L; Du W; Jia J
    J Int Med Res; 2020 Dec; 48(12):300060520980205. PubMed ID: 33350871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.
    Meriggi F; Codignola C; Beretta GD; Ceresoli GL; Caprioli A; Scartozzi M; Fraccon AP; Prochilo T; Ogliosi C; Zaniboni A
    Tumori; 2017 Sep; 103(5):443-448. PubMed ID: 28731495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.